

Data on Vildagliptin and Vildagliptin plus Metformin Combination in Type-2 Diabetes Mellitus (T2DM) Management

Das S, et al. Bioinformation. 2021 Mar 31; 17(3):413-423.

- Vildagliptin therapy was used for 24 months in 9,678 T2DM patients (median age, 52.0 years) and associated complications (peripheral neuropathy, CAD, nephropathy, retinopathy, autonomous neuropathy, stroke/TIA, and peripheral artery disease).
- The target glycemic control was achieved in 95.3% of patients.
- The mean HbA1c levels were significantly decreased post-treatment (-1.34%).
- Physicians rated the majority of patients as good to excellent on the global evaluation of efficacy and tolerability scale (98.9%, each).

Vildagliptin as monotherapy and combination therapy of vildagliptin and metformin was an effective therapy in reducing HbA1c & in achieving target glycemic control and also was well tolerated in Indian patients with T2DM.